Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Forum Says 75% Market Share Could Save US Billions

As AAM Discourages Reducing Incentives For Patent Challenge And Early Generic Entry

Executive Summary

The Biosimilars Forum, in partnership with the Pacific Research Institute, has released a report that shows state-by-state cost savings for the US if biosimilars were able to capture a market share of 75%. Meanwhile, the Association for Accessible Medicines has also released its complete 2021 US Generic And Biosimilar Medicines Savings Report, discouraging reducing incentives for patent challenges and early generic entry.

You may also be interested in...



Biosimilars To Generate $215bn In Savings Through 2026, Says IQVIA

Biosimilar competition, spurred on by significant losses of exclusivity for major products like Humira, Stelara and Xarelto, will lead to significant cost savings for healthcare systems and patients over the next five years according to a recent report from IQVIA. While these entrants are set to limit growth in the branded pharmaceuticals space, innovation is set to continue driving global spending.

Biosimilars Forum’s New Executive Director Faces Down Challenge Of Interchangeability Confusion

Juliana Reed, who just moved from Pfizer to head the trade group, hopes scientific advances will eventually eliminate the need for the interchangeability designation, but for now the association is educating stakeholders in preparation for the 2023 launch of Humira biosimilars.

AAM Applauds HHS For Acknowledging Brand-Driven Cost Increases

The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel